Z-VAD-FMK

Catalog No.S7023

Z-VAD-FMK Chemical Structure

Molecular Weight(MW): 467.49

Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.

Size Price Stock Quantity  
USD 117 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • (A) LAN5 cells were untreated (top panels) or treated with 50 µM of the caspase inhibitor Z-VAD-FMK (bottom panels). Cells were co-treated with nothing (No Rx), 1 µM GSK-J4, or 1 µM venetoclax for 48 hours and assayed for apoptosis by flow cytometry.

    Science, 2018, 10(441), doi: 10.1126/scitranslmed.aao4680. Z-VAD-FMK purchased from Selleck.

    After treatment with 1.5 g/l matrine in the presence or absence of 10 nM Baf A1 or 20 nM rapamycin or 10 lM z-VAD-FMK (zVAD) for 24 hrs, the cell viability was measured by CCK-8 assay. Results were expressed as mean±S.E.M. representing at least three independent experiments. *P < 0.05, versus matrine alone group.

    J Cell Mol Med, 2017, 21(6):1171-1181. Z-VAD-FMK purchased from Selleck.

  • (A and B) Western blot analysis examining the effect of zVAD-fmk on the icaritin-induced apoptosis. The caspase inhibitor zVAD-fmk could significantly decrease the icaritin-induced cleaved caspase-3 expression. β-Actin protein levels indicate that an equal amount of protein was loaded into each lane.n=3. Mean±SD. bP<0.05, compared to the control group. eP<0.05, compared to the icaritin-treated group.

    Acta Pharmacol Sin 2014 35(4):531-9. Z-VAD-FMK purchased from Selleck.

    Active caspase-3 expression analysis. SW1116 cells were treated with ZBH-1205, CPT-11 and SN38 at 25 μmol/L for 48 h, in the presence or absence of Z-VAD-FMK (50 μmol/L, 1 h ahead of time). *P= 0.0345. Z-VAD-FMK(-) vs. Z-VAD-FMK(+). E: Cell cycle analysis. F: Apoptosis analysis. #P=0.0259. Z-VAD-FMK(-) vs. Z-VAD-FMK(+). ALL experiments were repeated three times.

    Arch Biochem Biophys, 2016, 604:74-85.. Z-VAD-FMK purchased from Selleck.

  • Effect on the RAS of CFZ, z-VAD-fmk, or CFZ + z-VAD-fmk treatments administered 5 or 12 days after C26 inoculation and control groups. Western blot analysis of ATF2 and pATF2. CP, ZP and UP were treated for 5 days; CT, ZT, UT and CC were treated for 12 days. CFZ (CP), z-VAD-fmk (ZP), CFZ + z-VAD-fmk (UP), PBS only (CC), healthy control (HC).

    Med Oncol, 2015, 32(4): 538 . Z-VAD-FMK purchased from Selleck.

Purity & Quality Control

Choose Selective Caspase Inhibitors

Biological Activity

Description Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.
Features A key compound for apoptosis studies.
Targets
Pan-caspase [1]
(THP.1, Jurkat T-cells)
In vitro

Z-VAD-FMK (10 mM) inhibits apoptosis in THP.1 cells. Z-VAD-FMK (10 μM) inhibits activation of PARP protease activity in control THP.1 cell lysates. Z-VAD-FMK (10 mM) inhibits the processing of CPP32 in intact THP.1 and Jurkat cells. [1] Z-VAD-FMK (50 μM) cotreatment abolishes the apoptotic morphology of camptothecin-treated HL60 cells. Z-VAD-FMK (50 μM) blocks camptothecin-induced DNA fragmentation in HL60 cells. [2] Z-VAD-FMK (50 μM) inhibits cell death following dSMN dsRNA-induced apoptosis in S2 cells. Z-VAD-FMK (50 μM) increases the percentage of transfected cells surviving from 26% to 63% in S2 cells. [3] Z-VAD-FMK (> 100 μM) enhances TNFα-induced neutrophil apoptosis, lower concentrations (1-30 μM) completely blocks TNFα-stimulated apoptosis in human neutrophils. [4] Z-VAD-FMK (10 mM) inhibits apoptosis in anterior stromal keratocytes. Z-VAD-FMK (10 mM) inhibits apoptosis in anterior stromal keratocytes detected with the TUNEL assay. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
GC1a M4TwS2Fxd3C2b4Ppd{BCe3OjeR?= NWTESG53PTEQvF2= NHXTeIEzPGh? MoDxbY5lcWOjdHXzJIEheHKxdHXjeIl3\SCnZn\lZ5Qh[WejaX7zeEBmfG:yb4Pp[IU> NV:xeGxSOjZzNkmwO|U>
HGL5 NHL2SHJCeG:ydH;zbZMhSXO|YYm= MnrCOVDPxE1? MmD0NlRp MVLpcoRq[2G2ZYOgZUBxem:2ZXP0bZZmKGWoZnXjeEBi\2GrboP0JIV1d3Cxc3nk[S=> M4HLflI3OTZ7MEe1
HepG2 M3;VcWFxd3C2b4Ppd{BCe3OjeR?= M17wdVIx|ryP NV[3NVdJOWh? MUXheJRmdnWjdHXkJJRp\SCjcH;weI91cWNiaX7keYN1cW:wIH;mJGlKUS1zMNMg M4j0VVI3OTZ2N{m1
BEL-7402 MUXBdI9xfG:|aYOgRZN{[Xl? M1;RdVIx|ryP MkezNYg> M{P4TIF1fGWwdXH0[YQhfGinIHHwc5B1d3SrYzDpcoR2[3Srb36gc4YhUUmLLUGwxsA> NFnGNnQzPjF4NEe5OS=>
CEF NV3nOZBCU2mwYYPlJGF{e2G7 M2TmNFAtOzNuNkesNVAx|ryP NVjXUplMOTWvaX6= NVzSfXdJ\G:5bj3y[Yd2dGG2ZYOgVHIh\W68eX3lJIFkfGm4aYT5JJRwKDRy78{FJIF1KDFyMN88US=> M1\FTVI3OTB{M{O5
SP2/0 MUTBdI9xfG:|aYOgRZN{[Xl? MnzvNVAx|ryP NGq5d4EycA>? MnnaSG1UVw>? M2XlSoJtd2OtczD0bIUh[XCxcITvd4l{KG:oIGPQNk8xKGOnbHzz NGm0S4wzPjB5NEezNi=>
HUVEC-2c MnfjRZBweHSxc3nzJGF{e2G7 MUm1NO69VQ>? NVKyZW5TPmh? Monj[IVkemWjc3XkJJRp\SCxeD3MSGwucW6mdXPl[EBifXSxcHjh[5k> M{XqXVI3ODJzN{K5
U1 NHTDe4NCeG:ydH;zbZMhSXO|YYm= NWfHNINvOC1zMEFOwG0> NHP4SlUzcA>? MlzZdoVlfWOnczDkdpVoNWmwZIXj[YQh[XCxcITvd4l{KGGwZDDzeYJ{\XG3ZX70JGhKXi1zIILldIxq[2G2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M3rJVlI2QThyOUSy
ACH-2 MWfBdI9xfG:|aYOgRZN{[Xl? MVmwMVIxOM7:TR?= MWeybC=> NFjIRlRz\WS3Y3XzJIRzfWdvaX7keYNm\CCjcH;weI9{cXNiYX7kJJN2[nOncYXlcpQhUEmYLUGgdoVxdGmlYYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NV7uT4tnOjV7OEC5OFI>
U1 MmrRT4lv[XOnIFHzd4F6 NVfsSFdsOTByzszN Mlv2Nog> M{XafIlvcGmkaYTzJINie3Cjc3WtNy=> NF;0V|gzPTl6MEm0Ni=>
A549/V16 NFPB[GhCeG:ydH;zbZMhSXO|YYm= MWG1NO69VQ>? M1z0W|Fp M3fQO5JmeHKnc4Pld{BVTy:WTT3pcoR2[2WmIHHwc5B1d3Orcx?= MX[yOVk1PjB|Mx?=
SGN NHvuV2pCeG:ydH;zbZMhSXO|YYm= NWDvelh{OjCvTR?= MXe0PIg> NHq4fG1p[XNibn:gbY5ndHWnbnPlJI9vKEGLRjygZ4FteGGrbjDlfJBz\XO|aX;uJI9zKGOnbHygZZBweHSxc3nz MkC2NlU5PzR4M{O=
HCT116  M{PoSWFxd3C2b4Ppd{BCe3OjeR?= NETlZ4U2OM7:TR?= M2XJO|Jp NUTGZ4R6cW6qaXLpeJMhfGinIHPlcIwh\GWjdHigbY5lfWOnZDDifUBFTF[S MYmyOVg3QDhzOB?=
DTK-SME NG\h[4lCeG:ydH;zbZMhSXO|YYm= M2XhPVUx|ryP NWG0TJJiOmh? M4jZN2ROW09? MnzDdIFzfGmjbHz5JIlvcGmkaYTzJJRp\SCjcH;weI9{cXNiaX7keYNm\CCkeTDieZBqfmGlYXnu[S=> MViyOVg1Ozh7Nx?=
HL-60 NIj1[o5CeG:ydH;zbZMhSXO|YYm= MUG1NO69VQ>? NFnIWFk1QGh? NXW0fVBLemWmdXPld{Bk\WyuIHTlZZRpKGOjdYPl[EBjgSCVS1mtTWkhfHKnYYTt[Y51yqB? NEjQbGQzPTh{NEC0Ny=>
U937 MULBdI9xfG:|aYOgRZN{[Xl? NF3GOJM2OM7:TR?= MUG0PIg> MorOdoVlfWOnczDj[YxtKGSnYYToJINifXOnZDDifUBUU0lvSVmgeJJm[XSvZX70xsA> Mn3QNlU5OjRyNEO=
A549 NUPSdXBCSXCxcITvd4l{KEG|c3H5 M1y5dFIxKM7:TR?= MXqyOIg> MmfQdoVlfWOnczDj[YxtKGSnYYToJINifXOnZDDifUBJTkOSIITy[YF1dWWwdB?= MmTtNlU4QTRzNEm=
HeLa MWfBdI9xfG:|aYOgRZN{[Xl? NFG5bpYyOM7:TR?= Mn;3OFhp NXG1W2d2\GWlbHnu[ZMhfGinIILheIUhd2ZiYYDvdJRwe2m|IHTyZY1ifGmlYXzsfS=> M3TPTVI2Pzd{NUS1
SGC-7901 MnL5RZBweHSxc3nzJGF{e2G7 NHzWPHAzOMLizszN MVqxbC=> MUjpcohq[mm2czD0bIUh[2WubDDk[YF1cCCrbnT1Z4VlKGK7IH;4ZYxqeGyjdHnu M{XRNFI2PzZ5MEe2
MCF-7 M4m1cGFxd3C2b4Ppd{BCe3OjeR?= MWSxNO69VQ>? MnrnNog> NEnPVpFqdmirYnn0d{B1cGViY3XscEBl\WG2aDDpcoR2[2WmIHL5JFND NHrHbFAzPTd{MkGxOC=>
A549 MYjBdI9xfG:|aYOgRZN{[Xl? NX3jW|ZlOTBizszN MnnVNlRp NXjwSHJLTE2VTx?= MWLwdo9ud3SnczDIRmMufHKnYYTl[EBCPTR7IHPlcIwhe3W{dnn2ZYwhLiCjdITlcpVifGW|IITo[UBkdGWjdnXkJHBCWlBiZYjwdoV{e2mxbh?= MUCyOVY5OzV4OB?=
U87 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXS1NO69VQ>? NXXhdXNkOWh? MWjy[YNwfmW{czDj[YxtKGe{b4f0bEBnem:vIGTNXkB1emWjdH3lcpQ> MVyyOVY5OTZ4OB?=
Neocortical Neuron M1Hyb25mfXKxdH;4bYNqfHliQYPzZZk> M4OwSVExOM7:TR?= NIDWVXgycA>? M3S0eYFvfGGpb37pfoV{KEixaXHtbYRmKEFvSX7keYNm\CCQZYXyc5RwgGmlaYT5 M3XGO|I2Pjd3MECx
Primary human placental cytotrophoblasts NYHHS5lSSXCxcITvd4l{KEG|c3H5 NI\kO4w{OM7:TR?= M131R|I1cA>? M4rqZmROW09? M3z5[JJmfmW{c3XzJJRp\SCrbnjpZol1cW:wIH;mJFEy|rJvSGPENkBjgSC2cnnjcI9{[W8EoB?= Ml;nNlU3PDJ3OUK=
MM NIT0eYtCeG:ydH;zbZMhSXO|YYm= MmP2OVDPxE1? NVLGXYdMOjCvaX6= NFK4N21x[XK2bImgbY5pcWKrdIOgV2hMNWmwZIXj[YQhKGOnbHyg[IVifGh? MXOyOVU{ODB7OB?=
DLD1 MV3BdI9xfG:|aYOgRZN{[Xl? NFvQZWEzOMLizszN NUW1VWNJOWh? MWrwZZJ1dHlicnX2[ZJ{\XNiY3XscEBieG:ydH;zbZMh[2G3c3XkJIJ6KFeVUEG= NVPjcGRVOjV3MkSyOFY>
MDA-MB-231 Mn;CR5l1d3SxeHnjbZR6KEG|c3H5 NYXW[mZ6OTEQvF2= NHP1fmIycA>? MVXheYdu\W62czDj[YxtKGSnYYToJIFnfGW{IFPIWWEhfHKnYYTt[Y51 NX7BTYl4OjV3MkG1NFE>
MKN28 MUTBdI9xfG:|aYOgRZN{[Xl? NWrvVWJ[OTEQvF2= NVrUdIJEOzCvaX6= Mn7wSG1UVw>? NWjwXoI2cW6qaXLpeJMhXE6ILd8xJJBtfXNiQ1jYMYlv\HWlZXSgZZBweHSxc3nz M2DvdlI2PTF|OU[w
HL-60 M131S2N6fG:2b4jpZ4l1gSCDc4PhfS=> NGLhWo8yODEQvF2= NXfhU3d2OWh? MXrEUXNQ MVpCpIlueHKxdnXzJJZq[WKrbHn0fUBw\iCWQ17Bd{11emWjdHXkJINmdGy| NVzmNFI2OjV3MEK5N|I>
AGS NF34fldCeG:ydH;zbZMhSXO|YYm= NHixfpMyOM7:TR?= MXKxbC=> Mn7udJJmfmWwdIOgZ5Vz[3WvaX6tbY5lfWOnZDDjcIVifmGpZTDv[kBk[XOyYYPlMVMtKC16LDDhcoQhNTlicILveIVqdnN? MXKyOVQ6OjJzNB?=
A549  M1jld2Fxd3C2b4Ppd{BCe3OjeR?= M{jiT|Ex|ryP M{KzUVI1cA>? NYfmb3Np[myxY3vzJGROSVNvaX7keYNm\CClbHXheoFo\SCxZjDjZZNx[XOnLUOgZY5lKFCDUmCgZY5lKGGyb4D0c5Rq[yClZXzsJIRm[XSq MlS5NlU1OzR7OEm=
INS-1 MmXRRZBweHSxc3nzJGF{e2G7 MX[1NO69VQ>? MmDQOog> MkTkSG1UVw>? MWHk[YNz\WG|ZYOgeIhmKHC{b4DvdpRqd25ib3[g[YFzdHliYYDvdJRwfGmlIHPlcIx{yqB? Mm[2NlU1OzB6OUe=
Primary hepatocytes  M1j3NGFxd3C2b4Ppd{BCe3OjeR?= MVK1NO69VQ>? NVHYNJRFOTiq NFLjSphqdmirYnn0d{BieG:ydH;zbZMhd2ZiaHXwZZRw[3m2ZYOgbY5lfWOnZDDifUBC[3RiRDDhcoQhXE6ILd8x MWGyOVQxPzV|OB?=
L929-A  NHfEZWNEgXSxdH;4bYNqfHliQYPzZZk> NF\SdGgzOMLizszN MoS2NlRp NIHNRotqdmirYnn0d{BVVkcQsT3pcoR2[2WmIHPlcIwh\GWjdHi= M4XYbFI2Ozl6NUSw
L929-N NGr3eoFEgXSxdH;4bYNqfHliQYPzZZk> MX2yNOKh|ryP MWKyOIg> MkTM[Y5p[W6lZYOg[IVifGhidnnhJIF2fG:lcnnu[UBVVkcQsTDwdo9lfWO2aX;u NX\4XIg{OjV|OUi1OFA>
Cytotoxicity Assay NHW3TFFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NFrycXozOM7:TR?= MUe0PIg> M17ZepBz\X[nboSgUWhOTC2rbnT1Z4VlKGOnbHyg[IVifGh? NGfkboEzPTN7MkGxOi=>
COS7 Ml7GT4lv[XOnIFHzd4F6 NHLDeJMyOM7:TR?= MViyOIg> NFjUb3dqdmO{ZXHz[ZMh[2G|cHHz[UA{NzdiYXP0bZZqfGmncx?= NHjENmczPTN6NECyOS=>
COS7 NGjl[lNCeG:ydH;zbZMhSXO|YYm= NVPrcFByOTEQvF2= MXu0PIg> NWHLOGoxeGG{dHnhcIx6KHC{ZY\lcpRm\CCIQ{GwNU1qdmS3Y3XkJINmdGxiZHXheIg> MkDNNlU{QDRyMkW=
A375 MojaRZBweHSxc3nzJGF{e2G7 MlvtN|DPxE1? NInKVo4zcA>? MV\wdoV3\W62czD0bIUh\HK3Zz3pcoR2[2WmIGDBVnAh[2ynYY\h[4U> MmCzNlU{PzZzMUW=
A549 M33zbWFxd3C2b4Ppd{BCe3OjeR?= NHztVms2OM7:TR?= Mn3jNlRp M2jOZ5JmfmW{c3XzJJJq[m:|b33lJIJqd2enbnXzbZMh[W6mIHHwc5B1d3OrczDjZZV{\WRiYomgJGNpcWqxbnfkZY4> NUn2[|VuOjV|NEm3PFE>
A549 NIjqT2NCeG:ydH;zbZMhSXO|YYm= M4XSRlIvPS1{Nd88US=> M2fOVFFp NGDD[Xpl\WO{ZXHz[ZMhfGinIIDvdJVt[XSrb36gc4Yh[XCxcITveIlkKGOnbHzzJIRmeGWwZDDvckBkd26lZX70doF1cW:wcx?= MXiyOVM1OjR{Nx?=
 NBL-W-S  NYLod|cxSXCxcITvd4l{KEG|c3H5 M3;vWFUx|ryP MXKxbC=> M4DheoZ2dGy7IILld4N2\XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgS2FPXC14MTD0doVifG2nboS= NX;kSml1OjV|MkOyNlI>
Caki-1  NYHTWo9VSXCxcITvd4l{KEG|c3H5 M4n5NVQx|ryP M3HDTFQ5cA>? NVHsOIZbemWmdXPld{B1cGViboXtZoVzKG:oIFHucoV5cW5iVj3wc5NqfGm4ZTDj[Yxtew>? NYTpdmprOjV{N{mxPVE>
769-P NFH0b5FCeG:ydH;zbZMhSXO|YYm= MlfJOFDPxE1? M2fWeFQ5cA>? NYi2fGdwemWmdXPld{B1cGViboXtZoVzKG:oIFHucoV5cW5iVj3wc5NqfGm4ZTDj[Yxtew>? MX6yOVI4QTF7MR?=
H9c2 NEC4VI9CeG:ydH;zbZMhSXO|YYm= MWG1NO69VQ>? MW[xbC=> M1qyXolvcGmkaYTzJGRQYC2rbnT1Z4VlKGOjc4Dhd4UhOyCjY4TpeoF1cW:wIHL1eEBvd3RidHjlJIxwe3Nib3[gZ4VtdHN? MWSyOVI5OzhzOR?=
K562 NVLVXXV5SXCxcITvd4l{KEG|c3H5 NIjmZ4U2OM7:TR?= MVq0bC=> M3LFOolvcGmkaYTzJGpi[y2DLXnu[JVk\WRiY3XscEBieG:ydH;zbZM> MkjkNlUzPDF4MUm=
L929 M1fNNWFxd3C2b4Ppd{BCe3OjeR?= MUGxNO69VQ>? MYW2bC=> NWjMTmV1cW6mdXPld{Bv\WO{b4D0c5NqeyC5aYToJHRPTg>? MXGyOVE6PTZ4MB?=
A549 MWHBdI9xfG:|aYOgRZN{[Xl? NUTkOXR6OTEQvF2= NFiy[mY{cA>? NX\DS5pqemWmdXPld{Bk\WyuIHHwc5B1d3OrczDjZZV{\WRiYomgVHFS NWrSeFF7OjVzNkG2PVk>
MCF-7 NXzTWHd5SXCxcITvd4l{KEG|c3H5 MXyyNO69VQ>? NFHaZ5IzcA>? MljK[IVkemWjc3XzJGtFWi2|aWLORU1qdmS3Y3XkJIFxd3C2b4Ppdy=> MV[yOVE5OjJ2MB?=
OS MknhRZBweHSxc3nzJGF{e2G7 NYDadIJTOjBxNEFOwG0> NHP5OoY4Omh? NEPte4NqdmirYnn0d{BQWyClZXzsJJZq[WKrbHn0fUBz\WS3Y4Tpc44h[nliQ{[gZ4Vz[W2rZHW= MlLUNlUyPTJ|OUm=
HUVECs MkW0RZBweHSxc3nzJGF{e2G7 M3e3eFEx|ryP MmPVNog> MWVCpIlvcGmkaYTzJIFxd3C2b4Ppd{BidmRiZnHjbYxqfGG2ZYOgZZV1d3CqYXf5JIlvKESHTm[yMYlv\mWldHXkJGhWXkWFcx?= MnHxNlUyOzh5MEO=
EA.hy926 M4XvfGFxd3C2b4Ppd{BCe3OjeR?= NYrSb3l4OTEQvF2= M4P0WFJp NVvjbXl4yqCrbnjpZol1eyCjcH;weI9{cXNiYX7kJIZi[2muaYTheIV{KGG3dH;wbIFogSCrbjDESW5XOi2rbn\lZ5Rm\CCHQT7ofVkzPg>? Mn\kNlUyOzh5MEO=
Ebs NVHoWGtYSXCxcITvd4l{KEG|c3H5 NHXnNpQyOC1zMEFOwG0> M{CwfFI1cA>? MWpCpG1OXFNiZ3Xu[ZJifGmxbjDyZZRmKGSnY4LlZZNm\CCjczD0bIUh[2:wY3XueJJifGmxbjDv[kB7NV[DRD7mcYshcW6lcnXhd4Vl MXyyOVE{PDhzNx?=
Jurkat M2XS[WFxd3C2b4Ppd{BCe3OjeR?= MkTVNlDPxE1? NFHNcG0zPGh? MnzpSG1UVw>? NELUbY1x[XK2aXHscJkhcW6qaXLpeEBk\WyuIHTlZZRpKG:oIFr1dotifCClZXzsd{BqdmS3Y3XkJIJ6KDFyMEW4MWY1KGOxbXLpcoVlKHerdHigWnBCyqB? Mnn3NlUyOjB5MkO=
K562 MUnBdI9xfG:|aYOgRZN{[Xl? NUnIfYg3OC5zLUJOwG0> NWfxWFRDOWh? MmPvbY5pcWKrdIOgZ4xm[X[jZ3Wgc4YhUFOSOUCgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NUfZXW1{OjVzMUmxPFg>
IMR-32 MWPBdI9xfG:|aYOgRZN{[Xl? NI\mcoI1OMLizszNxsA> NFjkeJYzcA>? NF3ZXFFl\WO{ZXHz[UBqdiCjcH;weI91cWNiY3XscJMh[2:vcHHy[YQhfG9iVD2yJJRwgGmw NXz3fFVDOjVyOES3OVU>
RPMI 8226 NXvMTY1mSXCxcITvd4l{KEG|c3H5 NIPnZosyODEQvF2= NV\WSGJYOWh? NEnrNXZidG2xc4SgZ49ueGyndHXsfUBjdG:la4OgZ4VtdCCmZXH0bEBk[XW|ZXSgZpkhdmWlcn;zeIF1cW5vMR?= MV[yOVA{Pzh3MR?=
U266  MXXBdI9xfG:|aYOgRZN{[Xl? MXKxNFDPxE1? M2q3RVFp NIq0S3Fx[XK2aXHscJkh[myxY3vzJINmdGxiZHXheIgh[2G3c3XkJIJ6KG6nY4Lvd5RifGmwLUG= MXuyOVA{Pzh3MR?=
H929  M1PLWmFxd3C2b4Ppd{BCe3OjeR?= MknzNVAx|ryP MmDzNYg> M{nZO5BienSrYXzsfUBjdG:la4OgZ4VtdCCmZXH0bEBk[XW|ZXSgZpkhdmWlcn;zeIF1cW5vMR?= NET1SFczPTB|N{i1NS=>
MM.1S  MluxRZBweHSxc3nzJGF{e2G7 NFrpOGQyODEQvF2= MWGxbC=> M4rFVYVn\mmlaXXueIx6KHC{ZY\lcpR{KHOxcnHm[Y5q[i2rbnT1Z4VlKGOnbHyg[IVifGhiY3;tZolv\SC5aYToJI5m[3Kxc4TheIlvNTF? NGnsSlgzPTB|N{i1NS=>
C6 MlriRZBweHSxc3nzJGF{e2G7 NXfOWmdPPTEQvF2= M4rRRVQ5cA>? M2XqOpBz\X[nboTzJJRp\SCub4PzJI9nKGOnbHygeoli[mmuaYT5JINifXOnZDDifUBxemWpbnXuc4xwdmV? NIrtfnMzPTBzM{S3PS=>
AGS M4TUVWFxd3C2b4Ppd{BCe3OjeR?= M3fRUlUx|ryP NVvmRpB5OjSq Ml3jZYJwdGm|aIOg{tIudGGyYXPoc45mNWmwZIXj[YQh[2WubDDk[YF1cCCjbnSgbY5pcWKrdHXkJIdzd3e2aB?= MYOyOVAxQTZ7OB?=
HeLa  NVXnSJR[SXCxcITvd4l{KEG|c3H5 MlrYOFDPxE1? NEXreY0zPGh? NHz5PWhqdmirYnn0d{B1cGViaX7jdoVie2WmIHHwc5B1d3OrczDpcoR2[2WmIHL5JJNqWk6IMUKx MYCyOFkzQDZ6NR?=
THP-1  NIHHXGtCeG:ydH;zbZMhSXO|YYm= NXK2elQxOTEQvF2= MYKxbC=> Mlf2doVlfWOnczDhdI9xfG:|aYOgbY5lfWOnZDDifUBCVEFvU1TUxsA> MnHZNlQ6OjN4NUO=
P815  M1;rXGFxd3C2b4Ppd{BCe3OjeR?= MV[xNFAhyrWP MorrNVJp NW\OTlZTTE2VTx?= M1;2VIlvcGmkaYTzJJZqenW|LXnu[JVk\WRiYYDvdJRwe2m| NUf6dWZ1OjR7MkOyO|M>
HCT116 Mnz0RZBweHSxc3nzJGF{e2G7 NX\DdVYzOjEQvF2= NXvaSnV7OjSq NXXGd4Uy[WK{b3fheIV{KG:oIGTRMYlv\HWlZXSgZZBweHSxc3m= MVOyOFg6ODR2OR?=
SW1116  M4TscWFxd3C2b4Ppd{BCe3OjeR?= MUixNEDDvU1? MoD2NYg> NFPxWXlFVVOR M4jjUpJme3S{YXnud{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JIdm\mm2aX7pZkBxdHW|IHTlZ4l1[WKrbnW= NEjM[VUzPDh5NEK4Oi=>
LOVO MYHBdI9xfG:|aYOgRZN{[Xl? NGDGV5IyOCEEtV2= NILRWFkycA>? M4nqcWROW09? MYny[ZN1emGrboOgZ4VtdCCjcH;weI9{cXNiaX7keYNm\CCkeTDn[YZqfGmwaXKgdIx2eyCmZXPpeIFjcW6n M17rRlI1QDd2Mki2
SNU449  MY\BdI9xfG:|aYOgRZN{[Xl? MmDKNlDPxE1? MXS0PIg> NESyOplFVVOR NVXJfXBZ\GWlcnXhd4V{KG2rUj20OVEucW6mdXPl[EBieG:ydH;0bYM> MXGyOFg1OTZ|OB?=
Caco-2 M4HW[GFxd3C2b4Ppd{BCe3OjeR?= M4nF[VQx6oDLzszN NWHsTnBpPGh? NEKwZ|JxemW4ZX70d{BUXC15LXnu[JVk\WRiWl:tNUBkcGGwZ3XzJIFv\CCWRWKg[JJweA>? NYrteIVjOjR6MkKxPFM>
macrophage M4rMZ2NmdGxiVnnhZoltcXS7IFHzd4F6 NHjEZXkxNTJyMN88US=> MkC0NlRp M4Oxbolv\HWlZYOgWG5HNSCjbnSgVolxOy2mZYDlcoRmdnRibnXjdo9xfG:|aYOgbY4hdWGlcn;wbIFo\Q>? Mn7UNlQ4QTl3NkW=
AGS  MoTXRZBweHSxc3nzJGF{e2G7 NYP6[o9UOjEQvF2= NH7SSoQyOmh? NHXlZYxFVVOR MXfy[YR2[2W|IITo[UBqdmS3Y4Tpc44hd2ZiYYDvdJRwe2m|IHnuJJJme3CxboPlJJRwKHSqZTDFeG9C[yCocnHjeIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M{fOUlI1Pzh7N{Cz
LCC9  MWPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NVq3U|FxOTByzszN MWm1[C=> NVjOVZdl[myxY3vzJINmdGxiZHXheIghcW6mdXPl[EBjgSClb33ibY5ifGmxbjDMNVch[W6mIHPocI9zd3G3aX7l MVqyOFc5PTJ3Nh?=
U937  NILZ[Itv\WO{b4D0c5NqeyCDc4PhfS=> MmCwNVDDqM7:TR?= MXWzNOKhdWmw M2Psd4lv\HWlZYOgcoVkem:ydH;zbZMh[2:vYnnu[UB4cXSqIGTOSi=> NGm5[3EzPDd5M{e1Oi=>
T cell M3zGXmNmdGxicILvcIln\XKjdHnvckBie3OjeR?= M4TmWFAuOTByzszN MmTCO|Jp NFvoPHRKSzVyPUewJO69VSxiaX7obYJqfHNiYX70bU1ETDNvaX7keYNm\CCWIHPlcIwheHKxbHnm[ZJifGmxbjDpckBRSk2Fcx?= NF7LdGozPDd4OEewOy=>
HeLa  NH6xR5NCeG:ydH;zbZMhSXO|YYm= NVjPblJCPTEQvF2= M4\3XlczcA>? NXrYPYtmTE2VTx?= NVnOSIVweHKndnXueJMh[XCxcITvd4l{KGmwZIXj[YQh[nliY3;tdI92dmS|wrCx5qCUPQ>? MnTlNlQ4PTR5OE[=
HeLa  MlXQRZBweHSxc3nzJGF{e2G7 MVqxNFDPxE1? MVSyOIg> MYfzeZBxemW|c3XzJJJifGVib3[gZ4VtdCCmZXH0bEBqdmS3Y3XkJIJ6KG:4ZYLlfJBz\XO|aX;uJI9nKEd3OWOgc5IhTzdzUjDwNVUx\2y3ZXVCpC=> M2D3SVI1PzJ{NE[4
IEC-6  NETQcFNCeG:ydH;zbZMhSXO|YYm= NVKwc4VJOTEQvF2= M2XXV|I1cA>? NYXqfmpweHKndnXueJMhXGOmQT3pcoR2[2WmIHPhd5Bie2VvMzDjcIVifmGpZTDhcoQh|rJvY3H0[Y5qdiCmZXfyZYRifGmxbh?= M37qVFI1PzFzNUex
HCT116 MkT4RZBweHSxc3nzJGF{e2G7 NXvLdGw3OjEQvF2= MX:yOIg> MWnpcohq[mm2czD0bIUh[2WubDDhdI9xfG:2aXOgbY5lfWOnZDDifUB[VFR{MEW= MVqyOFcyOzhzMh?=
L02 NYTld5NFSXCxcITvd4l{KEG|c3H5 NHrFUJUzOM7:TR?= NELZUZcycA>? MXLwdoV3\W62czD0bIUh[2WubDDhdI9xfG:|aYOgbY5lfWOnZDDifUBOTUiS M2XmelI1PzB4NE[x
A375 Mn7wRZBweHSxc3nzJGF{e2G7 NHLyRm0zOM7:TR?= NELu[|gzPGh? NGrOU|Rz\X[ncoPld{BlcWOrdILpco9v\SCELXnu[JVk\WRiYYDvdJRwe2m| MXSyOFY6QTFzMR?=
HDPC NUjMTnZKSXCxcITvd4l{KEG|c3H5 MkT6OVDDvU1? MlywNlRp NVPaUmVRcW6qaXLpeJMhVk9vaX7keYNm\CCjcH;weI9{cXN? NGKySpEzPDZ|NEW5Ny=>
A549 NX;NW2p4SXCxcITvd4l{KEG|c3H5 MUm1NOK2VQ>? MVqybC=> Mon2SG1UVw>? NH3UeYJxemW4ZX70d{B1cGViaInwc4RqeGyxaXSgSG5CKGOxboTlcpQheGijc3WgbY5lfWOnZDDifUBk\XCqYXzvZ4hzd22rbh?= NH7pXlEzPDV6OEGzOS=>
 BV-2 MV\BdI9xfG:|aYOgRZN{[Xl? NFHrdmczOM7:TR?= M3zaV|Jp MnfRd5VxeHKnc4Pld{BWXi2rbnT1Z4VlKGOqcn;tZZRqdiCneITyeZNqd25iYX7kJIRqdGG2aX;uJI9nKHSqZTDueYNt\WG{IHXueoVtd3Cn NYDZNnA1OjR3NUixNVg>
HT-29  MkXNRZBweHSxc3nzJGF{e2G7 MoW0OVDPxE1? M4e2W|Q5cA>? NUPq[2wx[myxY3vzJJRp\SCjcH;weI9{cXNiaX7keYNm\CCkeTDrZYVueG[ncn;s MWiyOFU1QTF5NR?=
A549 NWS1VWY{SXCxcITvd4l{KEG|c3H5 NWTzS4o5Pc7:TR?= NEL1bFgzPGh? NVPNbXAze3WycILld5NmeyB4ZdMgLGJMOTByNECpMYlv\HWlZXSgZZBweHSxc3nzxsA> Ml7iNlQ2Ojl6N{G=
MIA-PaCa-2 M3;vUmFxd3C2b4Ppd{BCe3OjeR?= Mnr4NlRp NHq3fnFjdG:la4OgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[U0{KGmwZIXj[YQh[nliYn;0bEBCNTR2M{[1OEBidmRicHHjcIl1[XinbB?= NYP1WHo6OjR3MUC5PVI>
Caki-1 NG\HO3VCeG:ydH;zbZMhSXO|YYm= Mlr6NlDPxE1? NF\XToEycA>? NFrPWnJqdmirYnn0d{BUS1BvaX7keYNm\CCjcH;weI9{cXN? MmCxNlQ2ODR4OEG=
CLL M{ni[2Fxd3C2b4Ppd{BCe3OjeR?= MVqyOe69VQ>? NVXFR2VHOWh? NULFeYhneGG{dHnhcIx6KGKub3Prd{BOVE5{MkO4MYlv\HWlZXSgZ4VtdCCjcH;weI9{cXN? M3HIVVI1PDZ5NkO0
SGC-7901 M4f1WmFxd3C2b4Ppd{BCe3OjeR?= MUGxNO69VQ>? NXTD[lAxOjSq M3XvTpBzd22xdHXzJJRp\SCFR1nJMYlvcGmkaYTl[EBk\WyuIHfyc5d1cCCrbjDTS2MuPzlyMTDj[Yxtew>? MUeyOFQ2PDR6OB?=
k1735 NWnVOGRWSXCxcITvd4l{KEG|c3H5 MXyyNQKBkc7:bR?= M4PuSlRp NXPWeZhucW6qaXLpeJPDqFOjbH3vcoVtdGFvaX7keYNm\CCjcH;weI9{cXN? MnuyNlQ1PTFzMU[=
HaCaT  NUjtVIViSXCxcITvd4l{KEG|c3H5 NX;QbpNLOTByzszN NUXwRnlmOWh? MnHnZox2dnS|IGXWRk1qdmS3Y3XkJIFxd3C2b4Ppd{BqdiCKYVPhWEBk\Wyucx?= NFK4[nUzPDN3Nkm5Oy=>
podocytes NGC2PXNCeG:ydH;zbZMhSXO|YYm= MljCNlAx|ryP NHq5XYI3cA>? M1TyNYlvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KDNuND3ES2U> MUGyOFM{Pzd5Nx?=
 KB M2rmfmFxd3C2b4Ppd{BCe3OjeR?= M2XCNVUx|ryP MVKyOIg> NYTTcWR7cW6qaXLpeJMhVGmlbz3BMYlv\HWlZXSgZ4F{eGG|ZT2zJIFv\CCSQWLQJIFkfGm4YYTpc44> NWjhVVVMOjR|M{e0PVI>
 HepG2  M3L0[GFxd3C2b4Ppd{BCe3OjeR?= NHTibWkyOM7:TR?= NWDyT45lOjSq MmjUdoVlfWOnczD2bY1mdnSrbjDjcIVifmGpZTDjZZV{\WRiYomgUHBU NIf0PIQzPDN{NUixOi=>
fetal rat lung fibroblasts  NX;TS2tDU2mwYYPlJGF{e2G7 MYq4NO69VcLi NXLjVWFTOWh? M4rnOYlvcGmkaYTzJGNie3Cjc3WtN{Bi[3Srdnn0feKh NWTsfpJZOjR|MUSxN|U>
PDL fibroblasts MlX1T4lv[XOnIFHzd4F6 M3e5TVgx|ryPwrC= MXOxbC=> NX7PSo5scW6qaXLpeJMhS2G|cHHz[U0{KGGldHn2bZR6yqB? NX;oOXZ[OjR|MUSxN|U>
MB49 Mof0RZBweHSxc3nzJGF{e2G7 MVeyNO69VQ>? NXrJNnRzOWh? NUC0S2hDemW4ZYLz[ZMhS01vaX7keYNm\CClZXzsJIRm[XSq NEjFdGczPDJ6MkSzNy=>
5637 NYHkZpU2SXCxcITvd4l{KEG|c3H5 Ml7UNlDPxE1? M3XSPVFp M2\GWJJmfmW{c3XzJGNONWmwZIXj[YQh[2WubDDk[YF1cA>? M1XnOlI1Ojh{NEOz
A549  NHfLWIhCeG:ydH;zbZMhSXO|YYm= NFu5e2MyODEQvF2= M{DZUVQ5cA>? NVTr[I8{e3WycILld5NmeyC2aHWgZZBweHSxc3nzJINifXOnZDDifUBxcXCncnnu[eKh MXKyOFI4OjJyMR?=
MCC-2 M3;EeWFxd3C2b4Ppd{BCe3OjeR?= NVu2WIE4OjBizszN MmjHOog> NIfrT4tFVVOR NIjud45jdG:la4OgbY5lfWOnZDDifUB{fGG3cn;zdI9zcW6nIHHwc5B1d3OrczDj[YxtKGSnYYTo MkPpNlQzPjJ4NUi=
ADF Ml3ORZBweHSxc3nzJGF{e2G7 MmXyOFDPxE1? NULLXpJiPmh? Mn\BbY5pcWKrdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkh[2inbX;0bIVz[XC7IIDseZMhYm6FbEK= MXmyOFIzQDJ|Mh?=
 U373  NEPsWXBCeG:ydH;zbZMhSXO|YYm= MVW0NO69VQ>? MkjsOog> MoT6bY5pcWKrdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkh[2inbX;0bIVz[XC7IIDseZMhYm6FbEK= NVe2RmJJOjR{MkiyN|I>
RKO-HIPK2i NXf3[JVSSXCxcITvd4l{KEG|c3H5 NVniRo9XPDEQvF2= MlHMOog> NFP1N|dqdmirYnn0d{BieG:ydH;zbZMhcW6mdXPl[EBjgSClaHXtc5Rp\XKjcImgdIx2eyCcblPsNi=> NEnaNJkzPDJ{OEKzNi=>
HEC-1B MWrBdI9xfG:|aYOgRZN{[Xl? MoG0NlDPxE1? NXrnR5BTOWh? MlG3doVlfWOnczDUVE1qdmS3Y3XkJIFxd3C2b4Ppd:Kh[2G|cHHz[U0{KGGwZDDjZZNx[XOnLUm= MWCyOFIyOzN3OB?=
4T1 NVfTRXFMS2WubDDWbYFjcWyrdImgRZN{[Xl? NVnxWmk6Oi53LUGw{txO M{OyNVRp MUTEUXNQ MWry[ZNkfWW|IITo[UBkgXSxdH;4bYNqfHlib3[gOHQyKGOnbHzzJIlv\HWlZXSgZpkhW1CGVDDpckBiKGOxbnPlcpRz[XSrb36g[IVx\W6mZX70JI1idm6nch?= M1fmdVI1OjB4MU[x
OS  MYDBdI9xfG:|aYOgRZN{[Xl? M1nJW|Ix|ryP MmDwOIg> NULacY02cW6qaXLpeJMhfGinIHPlcIwh\GWjdHigZ4F2e2WmIHL5JHBFXA>? NXHhPI9COjR{MES5N|c>
RPE NIjGRWVCeG:ydH;zbZMhSXO|YYm= MV2xNFDPxE1? Mlf6OFhp NUXxVW5reGG{dHnhcIx6KGmwaHnibZR{KHSqZTDjZYxx[WmwLUGgZY5lKC1{IHHjeIl3[XSrb36gZZMhf2WubDDhd{B1cGViY3HzdIF{\SCjY4TpeoF1cW:w NWrLU3RwOjR{MEKwOVI>
UD29a MYPBdI9xfG:|aYOgRZN{[Xl? MUC1NO69VQ>? NWr4OJJyOjSq MYTpcohq[mm2czD0bIUh[2WubDDk[YF1cCClYYXz[YQh[nliTmXUNy=> M2\FbFI1OTlyNUe0
SH-SY5Y  NI\xPIRCeG:ydH;zbZMhSXO|YYm= NYXaS|NOOTEQvF2= NXL4dnJFOjSq Ml3QZZR1\W63YYTld{Bk[XOyYYPlJIFkfGm4YYTpc44h[W6mIHPlcIwh\GWjdHigbY5lfWOnZDDifUBJVkVvMlTH NV\TT4p6OjRzNEW0OlM>
HeLa  M4[5bmFxd3C2b4Ppd{BCe3OjeR?= MU[xNE8zOM7:TR?= MYeyOIg> NWnHc5lrcW6qaXLpeJMhfGinIHHjeIl3cXS7IH;mJJRp\SCvYXrvdol1gSCxZjD0bIUhdWWvYnXyd{Bw\iC2aHWgZ4F{eGG|ZT3mZY1qdHl? NVXKcWxsOjRzM{eyOlY>
SCCVII  M{HGN2Fxd3C2b4Ppd{BCe3OjeR?= MYKyOe69VQ>? NESyelkycA>? MULpcohq[mm2czD0bIUh[2WubDDrbYxtcW6pIHHmeIVzKGSjc3H0bY5q[g>? NHK2[4QzPDF{NkS2OC=>
RAW 264.7 NIPSenVCeG:ydH;zbZMhSXO|YYm= MoDxNlDPxE1? NGjaNmQyQGh? NVvOb2NycW6lcnXhd4V{KEyFMz3JTU/Pui2jY4TpckBz[XSrbzDjc41x[XKnZDD0c{BGS1SYLV3PV{B1emWjdH3lcpQhd26ueR?= M4P0SVI1OTF4N{C3
A549  NUe2cJFCSXCxcITvd4l{KEG|c3H5 NEPUOJczNjYQvF2= MW[yOIg> M{DqN4Rm[3KnYYPld{Bwemmmb37pck1qdmS3Y3XkJIF2fG:yaHHnfUBieyC5ZXzsJIFv\CCOb4PzJI9nKM7Wz5jtJIFte29ib3PjeZJz\WRiZIXybY5oKGG3dH;wbIFocWNicILvZ4V{ew>? NHvGOVgzPDFyMkWyNi=>
UM-SCC-10A  NX;1VlBqSXCxcITvd4l{KEG|c3H5 MUe1NOK2VQ>? Mm\uNog> MlHUdoVlfWOnczDhdI9xfG:|aYOgbY5lfWOnZDDifUBpcWeqLXTvd4UhcXOxYXzhcpRwdGGldH;u[S=> NEe3[ZkzPDB7OEe1Ny=>
BGC-823 NHGzZVRCeG:ydH;zbZMhSXO|YYm= NFPROJEyOCEQvF2= MXGyOIg> Mn\MdoVlfWOnczD0[ZRz[W6mcnnu[U1qdmS3Y3XkJIFxd3C2b4Ppd:Kh M2nFRlI1ODl6NUGx
Nalm-6  MWHBdI9xfG:|aYOgRZN{[Xl? MXqyNO69VQ>? M1XPNVRp MWLpcohq[mm2czDjZZNx[XOnLUigZY5lKGOjc4Dhd4UuOyCjY4TpeoF1cW:wIHHu[EBRSVKSLUGgZ4xm[X[jZ3W= NWr2OpF3OjRyM{m5Olc>
KHOS  Ml;PRZBweHSxc3nzJGF{e2G7 MVu0NO69VQ>? NELwSFgzPGh? M4K0NYJtd2OtczD0bIUhcW6lcnXhd4VlKGOuZXH2ZYdmKG:oIHPhd5Bie2VvMzDhcoQhWEGUUDDpcoR2[2WmIHL5JGJDVUR|wrC= M{fLSFI1ODJ3M{[x
G292 Mo\uRZBweHSxc3nzJGF{e2G7 NVXvS3ByPDEQvF2= M{npPVI1cA>? M3f6c4Jtd2OtczD0bIUhcW6lcnXhd4VlKGOuZXH2ZYdmKG:oIHPhd5Bie2VvMzDhcoQhWEGUUDDpcoR2[2WmIHL5JGJDVUR|wrC= M2qzNFI1ODJ3M{[x
MG-63 MYnBdI9xfG:|aYOgRZN{[Xl? NInVNFE1OM7:TR?= MljXNlRp NYPjNnVk[myxY3vzJJRp\SCrbnPy[YF{\WRiY3zlZZZi\2Vib3[gZ4F{eGG|ZT2zJIFv\CCSQWLQJIlv\HWlZXSgZpkhSkKPRERCpC=> MY[yOFAzPTN4MR?=
EBV-transformed B cells M{LZcWFxd3C2b4Ppd{BCe3OjeR?= MnXuNlDPxE1? MVmybC=> NXzQZmRRTE2VTx?= M{jqNoJtd2OtczDhcpRqNUOGOECgZY5lKGGwdHmtR2Q5PiCjboTpZo9lgS2rbnT1Z4VlKGGyb4D0c5Nqew>? NIX2WW8zPDByOE[yPC=>
IM-9 B MUPBdI9xfG:|aYOgRZN{[Xl? MnvYNlDPxE1? MW[ybC=> MojFSG1UVw>? NVz5OopT[myxY3vzJIFvfGlvQ1S4NEBidmRiYX70bU1ETDh4IHHueIljd2S7LXnu[JVk\WRiYYDvdJRwe2m| M1uyblI1ODB6NkK4
CNE1 NYHHc5VtSXCxcITvd4l{KEG|c3H5 NH21NWozOM7:TR?= MWm0PIg> MX7icI9kc3NiTFutRU1qdmS3Y3XkJIFxd3C2b4Ppdy=> NYP4b2VzOjN7OEWwNlk>
CNE2 NGHEN2lCeG:ydH;zbZMhSXO|YYm= MVmyNO69VQ>? NGrrUIs1QGh? M1rkTIJtd2OtczDMT{1CNWmwZIXj[YQh[XCxcITvd4l{ MYeyN|k5PTB{OR?=
HL-60 NVm4R2k1SXCxcITvd4l{KEG|c3H5 NXPwcXc5PTEEtV2= M{LqSFFp M{DD[2ROW09? MojGbY5pcWKrdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkhSkFzNEW= NELsRWczOzl2OEe1NS=>
L929 MYfBdI9xfG:|aYOgRZN{[Xl? MlvmNU4zPeLCk{ZCpO69VcLi NHLyT2QzPGh? MUHheYdu\W62czDUUmbPuS2rbnT1Z4VlKG6nY4LvdJRwe2m|IHHu[EBifXSxcHjh[5k> MU[yN|k1OTd4OR?=
Jurkat MVvD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NIPHem8z|ryP MYG0bC=> M3LVfZJmfmW{c3XzJIdzd3e2aDDpcohq[mm2aX;uJIFv\CEQsj3jZZRmdmmwIHTlZ5Jm[XOnIHL5JGhUNUGVQR?= MYqyN|g6PjB4MR?=
RAW264.7  NF3SS4dCeG:ydH;zbZMhSXO|YYm= M1[ze|ExKM7:TR?= NYTsNmhqOjSq M1\vR4Rm[3KnYYPld{B1cGViYYDvdJRwe2m|IHnu[JVk\WRiYomgS2E> NFjlOY0zOzh{MEKwNy=>
A431  NGDNeVZMcW6jc3WgRZN{[Xl? M4LOZlQx|ryP MViybC=> NXHz[49n[myxY3vzJIZqe2W2aX6tbY5lfWOnZDDjcIVifmGpZTDv[kBk[XOyYYPld{BidmRiUFHSVC=> NXO4b5V4OjN6MECwOVg>
Jurkat NVjtZoRXS2WubDDWbYFjcWyrdImgRZN{[Xl? NUDGcJJGOjVvMUCw{txO M1Hpd|Zp NGTBblFqdmirYnn0d{B7NU[DLVPNT{1qdmS3Y3XkJINmdGxiZHXheIg> M4HjfFI{QTN|NUOy
COS-7  NHjUdI5HfW6ldHnvckBCe3OjeR?= NWjjclExPTEEtV2= MnSwNlRp NITU[VVi\m[nY4TzJJRp\SCycn;j[ZN{cW6pIH;mJGFVVjG|IIfpeIgheG:ueWGgeJJi[3S| Mnj3NlM6OzN{MEi=
CAL27 NX3DdYNkSXCxcITvd4l{KEG|c3H5 NGrsNHkyOCEQvF2= MoXMNog> NV;MO2ZQe3WycILld5NmeyCFdYKtUnB{NXKnZIXj[YQhfmmjYnnsbZR6KGK7IIXwJJRwKDlyJR?= M{\VflI{QTF5M{m2
THP-1  NFzSNnFCeG:ydH;zbZMhSXO|YYm= M37U[VExNTVyzszN MmnHNog> NE\LdoZqdmirYnn0d{BieG:ydH;zbZMhcW6mdXPl[EBjgSC2cnnweI9tcWSn MU[yN|kxODJ7OR?=
K562 MnvBRZBweHSxc3nzJGF{e2G7 NF7FfZUzOM7:TR?= M2Dhc|Q5cA>? MV3pcohq[mm2czDhdI9xfG:|aYOgbY5lfWOnZDDifUA1NU2X NV;5PGhOOjN6N{[4NlY>
HL-60 M3HrfmFxd3C2b4Ppd{BCe3OjeR?= M1TpUFExOM7:TR?= NUO3UHZ5OjSq MlzFbY5pcWKrdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkh[WKrZYThcoUh\Gm2ZYLw[Y5me8Li NVjCb2Q4OjN6NkW3O|g>
HeLa  MXTBdI9xfG:|aYOgRZN{[Xl? NYOyNHRsOjEQvF2= M4HyXVJp MYrpcohq[mm2czDEUW1RKGmwZIXj[YQh[XCxcITvd4l{ NXjwe4NOOjN6NkO5OlY>
U251 M2fsUmFxd3C2b4Ppd{BCe3OjeR?= NH[xO4kzOM7:TR?= NX:yfmN{OjSq MYrpcohq[mm2czDjZZN1cWOrbjDpcoR2[2WmIFeyM20heGijc3WgZZJz\XO2IHHu[EBieG:ydH;zbZM> NVjxTIVFOjN6MU[4NVY>
HL-60 NYGwdVBuSXCxcITvd4l{KEG|c3H5 NV;GSWZrPTEEtV2= M3XGTVRp MV;icI9kc3NidHjlJINt\WG4YXflJI9nKGOjc4Dhd4UuOyxiLUmsJIFv\CCSQWLQJIlv\HWlZXSgZpkhPnN? NHTqUIozOzhyNEewOi=>
Ec-109 MoPhRZBweHSxc3nzJGF{e2G7 MlXLNVAh|ryP NWn3T3lGPDiq M2TXWZJmeHKnc4Pld{BRTS2vZXTpZZRm\CCHYz2xNFkh[2WubDDhdI9xfG:|aYO= NEfPZnYzOzd6Mk[0NS=>
RKO MVHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M1XuSVExKM7:TR?= M{D0b|I1cA>? M2D0O4lvcGmkaYTzJJRp\SCmZXPy[YF{\SCxZjDj[YxtKH[rYXLpcIl1gSClYYXz[YQh[nliRFHC MnO4NlM4PThyNkS=
T98G MmezR4VtdCCYaXHibYxqfHliQYPzZZk> NYH2dGI{OS1zMEFOwG0> NV3nOXpUOjSq M3jZWYlueHKxdnXzJINmdGxidnnhZoltcXS7IHPveJJm[XSvZX70JJdqfGhiVGO= MV[yN|c3QTJ5NR?=
Jurkat NVe3T3VLS2WubDDWbYFjcWyrdImgRZN{[Xl? NH;IcVIyODBvMkCw{txO NEe1XHUzPGh? M1zPeolvcGmkaYTzJGhiSTRiaX7keYNmeyCjcH;weI9{cXNiZHXw[Y5l\W62IH;mJINwdmOnboTyZZRqd28EoB?= M1z4SFI{PzN{NEix
Molt-3  NX\PVZBJSXCxcITvd4l{KEG|c3H5 NXT1SGlyPTEQvF2= MnWwNog> MnzsdoVlfWOnczDt[YxifG:waX6tbY5lfWOnZDDhdI9xfG:|aYO= MWqyN|czPTBzMx?=
hMSC12 NIezXXpCeG:ydH;zbZMhSXO|YYm= M1vrblExOM7:TR?= NVftenc5PGR? NF\nc3JqdmirYnn0d{Bwe3Snb3flcolkKGO3bIT1doUucW6mdXPl[EBk\WyuIHTlZZRpKGGwZDDjZYxkcW[rY3H0bY9v NYexV4tYOjN4NUe4NlI>
HM7  MXTBdI9xfG:|aYOgRZN{[Xl? MWmyNO69VcLi MVGxbC=> MkjEZoxw[2u|IHHwbYN2dGG{ZX6gRUBi[2W2YYTlMYlv\HWlZXSgZ4F{eGG|ZT2zJIFkfGm4YYTpc44h[W6mIGDBVnAh[2ynYY\h[4U> NHPab2EzOzV6M{SxNi=>
Hep-2  NGTOe2VCeG:ydH;zbZMhSXO|YYm= NX;q[WZ2OjEQvF5CpC=> NUSxfnNxOjSq MXnEUXNQ NV3Lc5p6[WyuZY\pZZRmeyC2aHWg[IVkemWjc3Wgc4Yh[2WubDD2bYFjcWyrdImgbY5lfWOnZDDifUB{cWyrYnnubY4> MV[yN|U5ODB|Mh?=
HSCs MYjBdI9xfG:|aYOgRZN{[Xl? MYS1NO69VQ>? NGLLc28zPGh? Mm\USG1UVw>? MYrpcohq[mm2czDubYxwfGmwaXKtbY5lfWOnZDDEUmEh\GGvYXflJIlv\GmlYYTl[EBjgSCSQWLQJINt\WG4YXfl MmjrNlM1QTl6N{S=
HL-60  MnLWR5l1d3SxeHnjbZR6KEG|c3H5 MkXGNlDPxE4EoB?= MWKyOIg> NWHqRph3emWmdXPld{B1cGViY4n0c5RwgGmlIHXm[oVkfCCxZjDFdpk2 NX60OIdWOjN2OUS0PFA>
HA NV7yNVViSXCxcITvd4l{KEG|c3H5 NIPTSlY2OM7:TR?= M4XqOlI1cA>? MXPzeZBxemW|c3XzJJRp\SClbHXheoFo\SCxZjDQRXJRKGGwZDDjZZNx[XOnLUOsJE04NCCjbnSgMVkhcW6mdXPl[EBjgSCkb4L0[ZpwdWmkL2PBTGE> M4fzOFI{PDd3OUW2
C666-1 MV3BdI9xfG:|aYOgRZN{[Xl? MnuyOVDPxE1? MUWyOIg> NWP3WmJVe3WycILld5NmeyC2aHWgZ4xm[X[jZ3Wgc4YhWEGUUDDhcoQh[2G|cHHz[U0{NCBvNzygZY5lKC17IHnu[JVk\WRiYomgZo9zfGW8b33pZk9USUiD MXWyN|Q4PTl3Nh?=
Hepa1-6 MljqRZBweHSxc3nzJGF{e2G7 MoTZOVDPxE1? MUKybC=> NX;lOG5XcW6qaXLpeJMh[3W{Y4XtbY4h[W6mIILld5ZmemG2cn;sMYlv\HWlZXSgZZBweHSxc3nz MljZNlM1PDZ5NUO=
PLC/PRF/5c Mlj4RZBweHSxc3nzJGF{e2G7 MW[1NO69VQ>? NYP4ZYN1OWh? NXzPTGhQeHKndnXueJMh[XCxcITvd4l{KHS{aXfn[ZJm\CCkeTDDTW4> MX6yN|Q{QDh{NB?=
HCT116 M1nTfWFxd3C2b4Ppd{BCe3OjeR?= NVj6SYNIOTByzszN MXexMlVp NEj0W3RqdmirYnn0d{BQey2rbnT1Z4VlKGOnbHyg[IVifGh? NVrYe2RDOjN5NESzOVM>
HCEC MWHGeY5kfGmxbjDBd5NigQ>? NUfKcJlEPTEQvF2= NYHQd2toPzKq MnLNSG1UVw>? NFjCVJhz\XO2b4Lld{Bw\iC2aHWgco9zdWGuIFjDSWMheGinbn;0fZBm NUjYRpRFOjN5NEKwNVE>
Primary rat cerebral cortical neurons NHy2dZBCeG:ydH;zbZMhSXO|YYm= NVq0fWNnOTByzszN NGPmb2cycA>? NVLBU2JqeHKndnXueJMhS2RvaX7keYNm\CCjcH;weI9{cXNiYX7kJINmdGxiZHXheIg> NWexZXoxOjN5NEGzNVc>
MDA-MB-231  MljpRZBweHSxc3nzJGF{e2G7 NUnCTJVuOjYQvF2= MlzSNlRp NWjx[Y5j[WK{b3fheIV{KGO7dH;0c5hq[2m2eTDhcoQh[2ynYY\h[4Uhd2ZiY3HzdIF{\S1|IHHu[EBRSVKSIHnu[JVk\WRiYomgVoc{ MX:yOVM{PzV2NB?=
NLRP3-Tet-on-MC/9  M1\Ld2Fxd3C2b4Ppd{BCe3OjeR?= MV6xNE01OM7:TR?= MXyxNog> MYnheJRmdnWjdHXzJJRp\SClZXzsJIRm[XSqIHPheZNm\CCkeTDDRXBUNWG|c3;jbYF1\WRiTlzSVFMhdXW2YX70d{BqdiC2aHWgWIV1NW:wIIP5d5RmdQ>? MnLsNlM4ODN|OEm=
KNS42  NWW2VI5ySXCxcITvd4l{KEG|c3H5 MYm1NO69VQ>? NGfwd3EycA>? NX73XnN6emWmdXPld{Bk\WyuIHTlZZRpKGGwZDDjc41xdGW2ZXz5JIFjd2yrc3jl[EBk[XOyYYPlJFMwPyCjY4Tpeol1gSCrbjDy[ZNxd26|ZTD0c{BCSlRvMk[zM|JFTy:vZYTmc5JucW5iY3;tZolv[XSrb36= NV[4ZoF5OjN4OUGxOFU>
MCF-7  M4DlWGFxd3C2b4Ppd{BCe3OjeR?= NUjUTXhOOjEQvF5CpC=> MmPUO|Jp NWfDSJl5cW6qaXLpeJMh\XG3b3ytJIFv\CB2LV;IWE1u\WSrYYTl[EBieG:ydH;zbZM> MX2yN|Y4PTZ2Mx?=
hCMEC/D3  MVfBdI9xfG:|aYOgRZN{[Xl? NEPBV3EzPc7:TR?= NFXqPGU4Omh? MX7y[YR2[2W|IFz0fGEhcW6mdXPl[EBieG:ydH;zbZM> NHzKenUzOzZ4NUG5PC=>
Jurkat NYDuPFlKSXCxcITvd4l{KEG|c3H5 NU\jSY5jOTJwNT21NO69VQ>? MlnrNYg> NY\uc5Fz\G:|ZTDk[ZBmdmSnboTsfUB{fXCycnXzd4V{KFOSSD3pcoR2[2WmIGDhdk01KGOuZXH2ZYdmNCCSQWLQJINt\WG4YXflMEBFVkFiZoLh[41mdnSjdHnvckwh[W6mIHzvd5Mhd2ZidnnhZoltcXS7 MXOyN|Q1Ojl5Nh?=
CNE-1 M3TLdGFxd3C2b4Ppd{BCe3OjeR?= MkDFNlDPxE4EoB?= M2XUblI1cA>? NXTqTWZNcW6qaXLpeJMhWkGGMECxMYlv\HWlZXSgZ4VtdCCmZXH0bC=> MmPYNlM1OjZ6NUC=
HONE-1 NYHSZW96SXCxcITvd4l{KEG|c3H5 NVSxTFlCOjEQvF5CpC=> NX3uO4dOOjSq MnLybY5pcWKrdIOgVmFFODBzLXnu[JVk\WRiY3XscEBl\WG2aB?= MlPJNlM1OjZ6NUC=
astrocytes cell MXXBdI9xfG:|aYOgRZN{[Xl? MX60NO69VQ>? M3fBTlZp MnLUdoVlfWOnczDlZZJtgSCjcH;weI9{cXNiaX7keYNm\CCkeTDzeIF2em:|cH;ybY5m M{\aOVI{PDFzN{e4
U-937 MWrBdI9xfG:|aYOgRZN{[Xl? NWTJb4ZROTEQvF2= MkLnN|BucW5? MnLndJJmfmWwdIOgWG5HNWmwZIXj[YQhdmWlcn;weI9{cXN? M{fUSVI{PDFyN{S4
MDA-MB-231 MlzHRZBweHSxc3nzJGF{e2G7 NHTKVWIyODEQvF2= NYDXR2NrOWh? NFfBOItqdmirYnn0d{B{\W6|aYTpfoF1cW:wIITvJHRTSUmOIIXwc44hVVSGSDDkc5dvNXKnZ4XsZZRqd25? MU[yN|QxQDR{OR?=
HeLa  M3\JNGFxd3C2b4Ppd{BCe3OjeR?= MnT1NVAx|ryP NUe1cW9rOmh? Mm\YZoxw[2u|IFrSV{0yPSCLbnT1Z4V{KEGyb4D0c5Rq[yCFZXzsJGRm[XSq M4TrV|I{OzR2MES1
Ec109 M17wO2Fxd3C2b4Ppd{BCe3OjeR?= MVyxNO69VQ>? M3rvfVZp MWjicI9kc3NiYYDvdJRwfGmlIHPvcYJqdmG2aX;uJI9nKFSjdD3TcYFkVjdiYX7kJJJi\GmjdHnvci=> MYeyN|M{QDV4OB?=
H460  MWrBdI9xfG:|aYOgRZN{[Xl? M{K0clEx|ryP NVe0dI1TPmh? MkDaZoxw[2u|IHHwc5B1d3SrYzDjc41jcW6jdHnvckBw\iCWYYStV41i[055IHHu[EBz[WSrYYTpc44> NV7lWYFxOjN|M{i1Olg>
HeLa  NFjsVG1CeG:ydH;zbZMhSXO|YYm= MVS1NO69VQ>? MXOxMlVp MnnkZYJzd2ejdHXzxsBEcGyjbYnkbYEucW6mdXPl[EBieG:ydH;zbZM> M1;JVVI{OzB|OEC0
SK-HEP1 NX;6cmhUSXCxcITvd4l{KEG|c3H5 NInrNpEyODEQvF2= MVuxbC=> MXTpcohq[mm2czDDdnQyKGGldHn2ZZRm\CClYYPwZZNmNTNuID23MEAuQCxiLUmsJIFv\CCyb3z5LGFFWC2{aXLvd4UqKHCxbInt[ZJie2V? NXrVd4tDOjN|MEK2OVA>
QGY7701 MVnBdI9xfG:|aYOgRZN{[Xl? MWGyOe69VQ>? MnTLNU42cA>? NETWdpNqdmirYnn0d{Bi[2O3bYXsZZRqd25ib3[gd5VjNUdzIIDoZZNmKGmwZIXj[YQh[nliRF;YJEsheXWncnPleIlv MknKNlMzPDByNkG=
HepG2 MYjBdI9xfG:|aYOgRZN{[Xl? M1jEVlIx|ryP NIXrWpk{OG2rbh?= MWLpcohq[mm2czD0bIUh\W6qYX7j[YQh[2WubDDk[YF1cCCkeTDjc41jcW6nZDD0doVifG2nboSgc4Yh[XCrZ3XubY4h[W6mIGTSRWlN MXyyN|IzPDJ|OR?=
U87  NH;PfmFCeG:ydH;zbZMhSXO|YYm= MV6yOe69VQ>? NGq3e|MzcA>? M{nN[YRm[3KnYYPld{Bqe2:uaYH1bZJqfGmpZX7pckApUVOOKT3pcoR2[2WmIHHwc5B1d3SrYzDj[YxtKGSnYYToMEBjfXRibn;0JI5m[3KxdHnjJINmdGxiZHXheIg> Mk\kNlMzOjl4Mk[=
HSC-2 NFG4NJhCeG:ydH;zbZMhSXO|YYm= MVeyOU82OM7:TR?= M1HsclFp M1LIUolvcGmkaYTzJHNPNTN6LXnu[JVk\WRiY4n0c5RwgGmlaYT5 MY[yN|E2PTJ2OB?=
HSC-4 NWDseZJOSXCxcITvd4l{KEG|c3H5 M3OxcFI2NzVyzszN MUexbC=> NFnCNG1qdmirYnn0d{BUVi1|OD3pcoR2[2WmIHP5eI91d3irY3n0fS=> NXzmcYJWOjNzNUWyOFg>
CL-1 NGL1eIhCeG:ydH;zbZMhSXO|YYm= MnG1NlDPxE1? M4e1bVFp Mly5Zoxw[2u|IF;QOFQ6KGmwZIXj[YQh[2WubDDk[YF1cA>? Mk\WNlMyOzF5OEK=
MEL NUe5XVRnSXCxcITvd4l{KEG|c3H5 MkHjNlDPxE1? NH\4PXQzPGh? NIraTlRFVVOR M4O4V4lueGGrcnXzJHAzYDdvaX7keYNm\CCPRVygZ4VtdCCjcH;weI9{cXN? MWWyN|AyPDh6Nx?=
Bel-7402  M{LwWGNie3Cjc3WgRYN1cX[jdHnvckBCe3OjeR?= MYW1NO69VQ>? NF;IN4QzcA>? NVTuVXBbcW6qaXLpeJMhWEOHLXnu[JVk\WRiYX7vbYtqew>? NUP5bHFROjNyMEi3OFI>
Eca-109 MnnORZBweHSxc3nzJGF{e2G7 MWmyOe69VQ>? MorEN|BucW5? NWLlOIZxcW6qaXLpeJMhSkpvQkGxMYlv\HWlZXSgZ4VtdCCmZXH0bC=> NIn1S4YzOzB5Nkm2Oy=>
MEL MoDRRZBweHSxc3nzJGF{e2G7 M{DmVVIx|ryP NU\JbJNzOWh? M4C1VGROW09? MV;pcZBicXKnczDQNng4NWmwZIXj[YQhVUWOIHPlcIwh[XCxcITvd4l{ MnrZNlMxOTR6OEe=
Bel-7402  NWnJcXZqSXCxcITvd4l{KEG|c3H5 Mk\UOVDPxE1? MX[ybC=> NIruU3BqdmirYnn0d{BRS0VvaX7keYNm\CCjbn;pb4l{ MVqyN|AxQDd2Mh?=
L929 MnXCSpVv[3Srb36gRZN{[Xl? MmrGNk42|ryP MnX5NYg> MoixbY5kemWjc3XzJHJKWDFiZYjwdoV{e2mxbjDhcoQh\XijY3XyZoF1\WRiVF7G{tEucW6mdXPl[EBucXSxY3jvcoRzcWGuIHT5d4Z2dmO2aX;uJIFv\CCUT2OgdJJw\HWldHnvci=> NV;kdFd[OjNyMEC1NVg>
RCC  MXTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NF;HU4UyODEQvF2= NIfRZ2EzPGh? MmCxdoVkd3[ncnXzJJRp\SC4aXHibYxqfHlib3[gZ4VtdHNiZYjwc5Nm\CC2bzCxOYQuWEeMMh?= NWLvcmt4OjJ7OUG0PVQ>
NB2a/d1 M{XRWWFxd3C2b4Ppd{BCe3OjeR?= MY[xNFDPxE1? MVe3Nog> NHfZR|difHSnboXheIV{KHO2YYXyc5Nxd3KrbnWtbY5lfWOnZDDjZZNx[XOnIHHjeIl3cXS7LDDQRXJRNCCjbnSgeIF2KGOuZXH2ZYdm MX6yNlk5QDV2MR?=
T cell NH[wZm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\YUYQzPS1zMEFOwG0> M4\5NlI1cA>? M4[5OYRwe2VvZHXw[Y5l\W62bImgbY5pcWKrdHXkJHQh[2WubDDwdo9tcW[ncnH0bY9vKG2nZHnheIVlKHSqcn;1[4ghfGinIHPvMZN1cW23bHH0bY9vKHerdHigZY51cS2FREOgZY5lKGGwdHmtR2QzQA>? M{XDclIzQTh{NUO4
K562 M{Hw[GFxd3C2b4Ppd{BCe3OjeR?= M{jGPFExOM7:TR?= MVyxbC=> MkS5Zoxw[2u|IFHico9j[X[rc3P1ceKhTi2rbnT1Z4VlKGGyb4D0c5Nqew>? MWqyNlk4OjN5Mh?=
Jurkat  NYPQbodmSXCxcITvd4l{KEG|c3H5 Ml;EOFDPxE1? M{n1WlFp MULhZo9tcXOqZYOgSoF{VC2rbnT1Z4VlKGOjc4Dhd4Uh[WO2aY\heIlwdiCjbnSgZ4VtdCCmZXH0bC=> NXLWTGtXOjJ7NEK3N|g>
BGC-823 NFLqO49CeG:ydH;zbZMhSXO|YYm= M1HTSlExOM7:TR?= NHrSSWoycA>? M1OzWpBienSrYXzsfUBz\XOldXXzJINmdGy|IHHnZYlve3RiZHHtZYdmKG:oIHThbYR7\Wmw NHLPZ2IzOjl{NkW0OS=>
Hep3B MX;BdI9xfG:|aYOgRZN{[Xl? NXHoZpc3PTEQvF2= MYSxbC=> M3n0dIJtd2OtczDhdI9xfG:|aYOgbY5lfWOnZDDifUBJTUeFcx?= M1nGTlIzQTJ|MUW0
LLC-PK1 Ml;lRZBweHSxc3nzJGF{e2G7 NH\DbGYzOM7:TR?= MVexbC=> M{PjTZBz\X[nboTzJINqe3CuYYTpck1qdmS3Y3XkJIRm\3KjZHH0bY9vKG:oIFH0[|UtKGKnY3zpck0yNCCjbnSgRZRoOTJicILveIVqdnN? MX:yNlg6PjB|Nx?=
A549 NUjxNJR4SXCxcITvd4l{KEG|c3H5 NFXwenI2OM7:TR?= Ml;xNYg> Mmm3Zoxw[2u|IITo[UBDSUlvaX7keYNm\CCjcH;weI9{cXQEoB?= NF\rTZMzOjh6N{KxOS=>
SGC-7901  NFnnb5BCeG:ydH;zbZMhSXO|YYm= MoDLNVDPxE1? NUPvNohmOjSq MXnpcohq[mm2czFOtkzPui2maX3leIh6dGGlconsd4hqc2:waX6tbY5lfWOnZDDhdI9xfG:|aYRCpC=> M3\T[lIzQDR6NUm3
DM6 MXvBdI9xfG:|aYOgRZN{[Xl? M3rPeVExOM7:TR?= NWTrb5JGPzKq M{f2XoJtd2OtczDic5RpKEV{Rj2xJIFv\CCHMl\0dk1u\WSrYYTl[EBkgXSxdH;4bYNqfHl? M{LGUlIzQDJ3M{K4
MCF-7, MDA-MB-468, Caco-2 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HzVVUx|ryP NVX6bYxbPDiq M1;RXYlvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDpcohq[mm2aX;uJIlv\HWlZXSgZpkhe2Gyb37pci=> M4LOclIzQDByOU[4
A2750  NHPWU2hCeG:ydH;zbZMhSXO|YYm= MojjNlDPxE1? NVryVFBZOmh? MXnEUXNQ NUW1ZlVy[myxY3vzJINie3Cjc3WgZ4xm[X[jZ3Wg[JVzcW6pIHjlcIVv[WyrbjD0doVifG2nboSgZY5lKHKnZIXj[ZMh[XW2b4DoZYdq[yClZXzsJIRm[XSq NHHtepUzOjd6NEO2Ny=>
U87  M2LI[WFxd3C2b4Ppd{BCe3OjeR?= MoDINlDPxE1? MVqyOIg> MX;y[YR2[2W|IITo[UBieG:ydH;zbZMhemG2ZTDpcoR2[2WmIHL5JHBNSUJ? NE\SN3MzOjd5OEe4NC=>
HT1080 MorPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTJbFVUPTEQvF2= M2fXc|dl M2e5c4lvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDpcohq[mm2aX;uJINifXOnZDDifUBkd22kaX7l[EB1emWjdH3lcpQhd2ZiRFPBJIFv\CCRTWC= NWnjSVRvOjJ5NEC5PFQ>
A549  M121RWFxd3C2b4Ppd{BCe3OjeR?= NFLWZmk2OM7:TR?= NGXHXY8zcA>? NEjhWWNx[XK2aXHscJkh\GWlcnXhd4V{KHOxZHn1cUB{\Wynbnn0[U1qdmS3Y3XkJIFxd3C2b4Ppdy=> M{K2ZlIzPzJzOEC0
Primary OPC NWDqe4JKSXCxcITvd4l{KEG|c3H5 MUSx{txO NX\GTmcxPmhxMkTo MWLy[YR2[2W|IITo[UBx\XKlZX70ZYdmKG:oIHPlcIx{KGmwIHXhdox6NSCjbnSgcIF1\S2jcH;weI9{cXNxbnXjdo9{cXN? NFLvbXkzOjdyN{O4OS=>
PMNs NGfG[HZCeG:ydH;zbZMhSXO|YYm= M2H1TlQx|ryP MonYOog> MUXEUXNQ NHX5N4Rz\X[ncoPl[EB1cGViYX3veY51KG:oIHPs[YF3\WRiY3HzdIF{\S1|IITvJI5m[XJidnXobYNt\SCuZY\lcJM> MXSyNlY6OjV5Nx?=
A549  MoTVRZBweHSxc3nzJGF{e2G7 NF\leY42OM7:TR?= NE[we5UycA>? NX;CUINIeHKndnXueJMh[XCxcITvd4l{KGmwZIXj[YQh[nliQnHvbJVwe2mmZTDJ MmDNNlI3QDd4M{W=
AGS NEf3WXBCeG:ydH;zbZMhSXO|YYm= MWiyNO69VQ>? NUTuRZpuOTKq M3vvOYlvcGmkaYTzJJRp\SCjY4TpeoF1cW:wIH;mJJBzdy2lYYPwZZNmNTNiaX6gdoV{eG:wc3WgeI8hfGinIFX0U2FkKG[{YXP0bY9v NFXxc4IzOjZ6N{O5PC=>
shC9  NX\xWG8{SXCxcITvd4l{KEG|c3H5 MWixNO69VQ>? NXjQSZBCOT[q NYS5eIZq[my3boTzJHNJUCCneIDy[ZN{cW:wIHnuJJNpSzliY3XscJMh\Xiyb4Pl[EB1dyCnaYTo[ZIhWEFib4KgUHBE MkTQNlI3PDFyOUS=
primary MEFs MoLHSpVv[3Srb36gRZN{[Xl? MUexNog> M3H5[:KhcW6lcnXhd4V{KGW2b4Dvd4ll\S2rbnT1Z4VlKG2rdH;jbI9v\HKrYXygcYVu[nKjbnWg[IVxd2yjcnn6ZZRqd25? NYXBO40yOjJ4MUO3Olc>
3T9 MEFs MWLGeY5kfGmxbjDBd5NigQ>? NUDzfYJwOT[q NUTZT3hPcW6lcnXhd4V{KGO7dH;jbJJwdWViYzDy[Yxm[XOnIHHmeIVzKGW2b4Dvd4ll\S22cnXheI1mdnR? NWXLbGQ3OjJ4MUO3Olc>
3T9 MEFs M2n0Z2Z2dmO2aX;uJGF{e2G7 MVKxPIg> M1fYSJVxemWpdXzheIV{KGmwaYTpZZRweiClYYPwZZNmNTliYoX0JIRwf26{ZXf1cIF1\XNiZX\m[YN1d3JiY3HzdIF{\XNiYX\0[ZIh\XSxcH;zbYRmKHS{ZXH0cYVvfA>? MXKyNlYyOzd4Nx?=
MDA-MB-231  NHf0bWpCeG:ydH;zbZMhSXO|YYm= MUKyNO69VQ>? NHm3THM1\A>? MmHjdoVlfWOnczD0bIUh[2WubDDhdI9xfG:|aYOgbY5lfWOnZDDifUBu\XSob4LtbY4hfHKnYYTt[Y51KHejczDzbYdvcW[rY3HueIx6 M4O1e|IzPTl|NESx
C6  MlHkRZBweHSxc3nzJGF{e2G7 NWDyZW9DOTEQvF2= NYDTS2ViOjSq M{niRoJtd2OtczD0bIUhe3WycILld5NqfmViZX\m[YN1KG:oIITo[UBx\XC2aXTlJI9vKH[rYXLpcIl1gQ>? NEj2V44zOjV6OEm4NC=>
HL-60  NWTZRndHSXCxcITvd4l{KEG|c3H5 NVXpb|lIOTByzszN MlrMNlRp NHS1VFFqdmirYnn0d{B1cGViY3XscEBieG:ydH;zbZMhe2WuZXP0[YQhMCtrLX3lcpRpgWxizsKtLFHjjpJ4KT3kbYdtfWOxcInyZY5we2mmZdMgOS=> M3rXXFIzPTR4Nk[5
HL-60 MX\BdI9xfG:|aYOgRZN{[Xl? NV;WR|BWOTBvOEFOwG0> NYe4WGZ2PGh? NUPIW5lLcW6qaXLpeJMhXEeKUT3pcoR2[2WmIHPlcIwh[XCxcITvd4l{yqB? NUPz[4V{OjJ3MkOyNlk>
BCC NF7YfWZCeG:ydH;zbZMhSXO|YYm= NITuSGo2OM7:TR?= M4X5RVFp NIXoTY1qdmirYnn0d{BFSVSVLX3l[IlifGWmIHfyc5d1cCCrbnjpZol1cW:w MYGyNlUyQTR|Nh?=
RAW 264.7 NFT1PY1CeG:ydH;zbZMhSXO|YYm= NIewdJU2OC9zMEFOwG0> NXXJWVNjOWh? MWrjc45k\W62cnH0bY9vNWSncHXu[IVvfCCrbnjpZol1eyCGT16tbY5lfWOnZDDyVm5CKGOuZXH2ZYdm NXHWW2tJOjJ2OUG0NlY>
K562 MWnBdI9xfG:|aYOgRZN{[Xl? M4\1bFI2|ryP NVTMVXBIOmh? MVLwdoV3\W62czDhdI9xfG:|aYOgbY5lfWOnZDDifUBkdy22cnXheI1mdnRid3n0bEBidXW{ZX7zbY4hTyCjbnSgWHJCUUx? NX7GVmFHOjJ2OEO3O|c>
SGC-7901 MWjBdI9xfG:|aYOgRZN{[Xl? NVHMboozOjBizszNxsA> MUGybC=> MVjheJRmdnWjdHXzJGgzVzMEoH;yJHRPTiEQsT3pcoR2[2WmIHPlcIwh[XCxcITvd4l{KGG|IIflcIwh[XNiY3HzdIF{\S1|IHHjeIl3cXS7wrC= M2nUcFIzPDdzNUi5
PC3 MV7BdI9xfG:|aYOgRZN{[Xl? NGrDTnIyOM7:TR?= NG\vfVg1cA>? NVXIZoM1[2:3boTldpMh\myjdn;jc5hq\C2rbnT1Z4VlKGOjc4Dhd4UuemWuYYTl[EBieG:ydH;zbZM> NV;yZW5MOjJ2N{G5O|Q>
SMMC-7721 MknvRZBweHSxc3nzJGF{e2G7 NInxSIs2OM7:TR?= NITOfI41QGh? M2rRfYF1fGWwdXH0[ZMhd1SULXnu[JVk\WRiYYDvdJRwe2m| M4nCSlIzPDZ3OEOz
HeLa  MlvhRZBweHSxc3nzJGF{e2G7 MoS5OVDDqM7:TR?= NIexSXo1Nziq NEju[VRqdmirYnn0d{BUXFNvaX7keYNm\CCuYYTlMZBp[XOnIHHwc5B1d3SrYzDleoVvfHN? MoPONlI1PjB3MES=
HeLa  M2HwVWFxd3C2b4Ppd{BCe3OjeR?= M{j2PFUxyqEQvF2= MmnUNYg> MWrzeZBxemW|c3XzJJRp\SCIUlHQMYlv\HWlZXSgZYNkfW23bHH0bY9vKG:oIHHucoV5cW5iVjDwc5NqfGm4ZTDj[Yxtew>? MXKyNlQ1QTR2MB?=
T47D  MkTYRZBweHSxc3nzJGF{e2G7 NW\EXJJROTByzszN M1HLelFp Mk\jZoxw[2u|IITo[UBo\W6ncnH0bY9vKG:oIFWtZ4FlN0OWRkKgZpkhW1SV NEWycZgzOjRyMUG2PC=>
HeLa  MYLBdI9xfG:|aYOgRZN{[Xl? NGntNnE{OM7:TR?= M4PzVlRp MYZCpIlv[3KnYYPld{B1cGViZ3Xu[ZJidCClZXzsJJZq[WKrbHn0fUA1QCCqIHHmeIVzKHCqb4Tv[Jlv[W2rYzD0doVifG2nboVCpC=> M2foW|IzOzl2MkS4
HCC M4DUUGFxd3C2b4Ppd{BCe3OjeR?= Ml23NlAh|ryPwrC= NWKzVVQ{Omh? MnLrZZR1\W63YYTld{B1cGViRFjBJIlv\HWlZXSgZYN1cX[jdHnvckBw\iCSQWLQ NWfB[XlKOjJ|NEK3N|I>
mESCs NYPaVm01SXCxcITvd4l{KEG|c3H5 MUeyMlXPxE1? M{PnflJp NUXZVHMycW6qaXLpeJMhfGinIF7hSk1u\WSrYYTl[EBk[XOyYYPlJIFkfGm4YYTpc44> MWqyNlI5PTJ5NB?=
EMT-6  MV3DfZRwfG:6aXPpeJkhSXO|YYm= NXzaZ2tyOTByzszN NXS0cYdZOWh? NIHPc29x[XK2aXHscJkh[myxY3vl[EBk\WyuIHTlZZRpKGmwZIXj[YQh[nlic3nyZY1me2mwZR?= NG\FcIozOjJ3MUmyNS=>
MCF7 M4GxcmFxd3C2b4Ppd{BCe3OjeR?= M1TOO|UxyqEQvF2= M1vzR|Fp MmDXbY5pcWKrdIOgVGEh[WO2aY\heIVlKGOjc4Dhd4UuOyxiLUmsJIFv\CCyb3z5LGFFWC2{aXLvd4UqKHCxbInt[ZJie2V? NI\4RokzOjJ{M{O0OS=>
K562 MnjHRZBweHSxc3nzJGF{e2G7 M4Lib|IxKM7:TdMg MYe0PIg> MVLEUXNQ Mk[wZoxw[2u|IHzhdIF1cW6rYj3pcoR2[2WmIHnubIljcXSrb36gc4YhfmmjYnnsbZR6KGGwZDDhdI9xfG:|aYOgbY5lfWO2aX;u MWiyNlIyPjF3OB?=
Molt4-hyg M3v1dWFxd3C2b4Ppd{BCe3OjeR?= M2XwPVEx|ryP NF7sepYxNjWq NYr4Rm04[myxY3vzJIZiem6nc3;sMYlv\HWlZXSgZ4F{eGG|ZT2zMYxqc2ViYXP0bZZqfHl? MUKyOlI4PThzMR?=
HeLa NFy2TW1CeG:ydH;zbZMhSXO|YYm= M{fvPVEx|ryP MV[wMlVp NXzw[GJOcW6qaXLpeJMh[XCxcITvd4l{KGmwZIXj[YQh[nlidHjlJINwdWKrbnXkJJRz\WG2bXXueEB4cXSqIHfvcYl{cW5iTjDhcoQhXFKDSVy= NYHL[nR{OjJzN{m2OlE>
Jurkat T MVHBdI9xfG:|aYOgRZN{[Xl? NGfaWGM{OM7:TR?= NXzKXWV4OC53aB?= MmPsSG1UVw>? M1rZbYJtd2OtczD0bIUhgmm{YX2tbY5lfWOnZDDhdI9xfG:|aYO= Mmn4NlIyPTl6OUi=
Neutrophil MUXBdI9xfG:|aYOgRZN{[Xl? NH3lNZUzOM7:TR?= NVrDNG9VOC53aB?= NEOwVHJifHSnboXheIV{KHSqZTDwdo8u[XCxcITveIlkKGWoZnXjeEBw\iCPYWKx NXz4bGY{OjZzOU[4OFQ>
HCT116 NXrQSYE5SXCxcITvd4l{KEG|c3H5 M1W5[FUxyqEQvF2= NHvsbGIzcA>? M4H6[ZJmfmW{c3XzJJN6dmW{Z3nzeIlkKGGyb4D0c5NqeyCnZn\lZ5R{KG:oIHPlcIVkd3irYjDhcoQhVlCFLUG2xsA> MmjoNlIyPTl5NUK=
MDA-MB-231  NHL5XGxCeG:ydH;zbZMhSXO|YYm= MnjRNk42NTdwNd88US=> M1TKOVJp NH3IUHdqdmirYnn0d{B1cGViY3XscEBl\WG2aDDv[kBOTEFvTVKtNlMyKGOnbHzzJIlv\HWlZXSgZpkhW0SWIHnuJIEh[2:wY3XueJJifGmxbjDk[ZBmdmSnboSgcYFvdmW{ NVfkPWRkOjJzMUW1NlY>
LNCaP M3\Nb2Fxd3C2b4Ppd{BCe3OjeR?= NEDDVWs1OM7:TR?= NFHjfVIzcA>? MVjpcohq[mm2czDieZRmcW5iaX7keYNm\CClZXzsJIFxd3C2b4Ppdy=> NWDmc251OjJzMUS3OlQ>
MB231 NXrzNJo{SXCxcITvd4l{KEG|c3H5 NGnuUGkyODEQvF2= NUjZdmhxOWh? MkfRSG1UVw>? MYPhZpJw\2G2ZYOgeIhmKGmwZIXjeIlwdiCxZjDj[YxtKGSnYYToJIJ6KFeHRUGgbY5pcWKrdHnvckwhXFKDSVygeJJm[XSvZX70MEBidmRidHjlJINwdWKrbnH0bY9v MYKyNlEyOjl2MB?=
HCC38  NYLpe2tFSXCxcITvd4l{KEG|c3H5 MnHLNVAx|ryP NU[0fGVlOWh? NGDaOlZFVVOR MlPnZYJzd2ejdHXzJJRp\SCrbnT1Z5Rqd25ib3[gZ4VtdCCmZXH0bEBjgSCZRVWxJIlvcGmkaYTpc44tKFSUQVnMJJRz\WG2bXXueEwh[W6mIITo[UBkd22kaX7heIlwdg>? NVL6eZNzOjJzMUK5OFA>
MDA-MB231 Mn;tRZBweHSxc3nzJGF{e2G7 NFTvNW42OMLizszN NVvqc3FoOjSq NW\YeGVJTE2VTx?= NVjQO2k3[WK{b3fheIV{KGO3cnP1cYlvNWmwZIXj[YQh[2WubDDk[YF1cA>? NVW4dXpROjJzMEGzN|U>
LNCaP M3PUTGFxd3C2b4Ppd{BCe3OjeR?= MWO1NOKh|ryP NEH0SoYzPGh? NX7yNVgzTE2VTx?= NXuxT5Zn[WK{b3fheIV{KGO3cnP1cYlvNWmwZIXj[YQh[2WubDDk[YF1cA>? MViyNlExOTN|NR?=
HCT116 M1TTc2Fxd3C2b4Ppd{BCe3OjeR?= M3jnT|UxyqEQvF2= Mo\WNlRp M17XOGROW09? MWrhZpJw\2G2ZYOgZ5Vz[3WvaX6tbY5lfWOnZDDj[YxtKGSnYYTo NXTzfnhHOjJzMEGzN|U>
Ishikawa  NUT0U|RRSXCxcITvd4l{KEG|c3H5 M4DkV|I2|ryP MnjaNlRp MoW1doVlfWOnczDj[YxtKGSnYYToJIFv\CCjcH;weI9{cXNiaX7keYNm\CCkeTDCZYYhSTF? NFjK[HgzOjB6OEmxPC=>
 YD-8  MlPwRZBweHSxc3nzJGF{e2G7 NHTKR|IyODEQvF2= MW[xbC=> M{[0WolvcGmkaYTzJHBNTU9vaX7keYNm\CCjcH;weI9{cXN? MoruNlIxQDZzOEO=
eosinophil  M4Hlc2Fxd3C2b4Ppd{BCe3OjeR?= M1nu[Fkx|ryP M2rIblI1cA>? NVvO[IxtcW6qaXLpeJMh[XCxcITvd4l{KGmwZIXj[YQh[nliRnHzJIFvfGmkb3T5xsA> M2TjXlIzODd7M{O0
L929 NI\OZWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1H5cFIvPc7:TR?= MXyyOIg> NHHmcoRqdmirYnn0d{B1cGViZYjwdoV{e2mxbjDv[kBxNXB|ODDhcoQhVkZvzsrCJJRwKGG3Z33lcpQhXE6IzsGtbY5lfWOnZDDu[YNzd3C2b4Ppd{BidmRiYYX0c5Bp[We7 NXXIXXpkOjJyMkewPVc>
YD-8  M1;MUmFxd3C2b4Ppd{BCe3OjeR?= NF3uc3UyODEQvF2= NGjLZnoycA>? NXjrbVJo[myxY3vzJJRp\SCJUz3IR4wucW6mdXPl[EBieG:ydH;zbZM> M3TqNVIzODJyMEe4
HBx MWLBdI9xfG:|aYOgRZN{[Xl? NXe5cJBrOjYQvF2= NWDjfFRtPDiq MV\EUXNQ M{jydpJm\HWlZXSgZ4VtdCCmZXH0bEBqdmS3Y3XkJIJ6KDNvTVG= NVTvcItrOjJyMkCwO|g>
U937  NGPKXGFCeG:ydH;zbZMhSXO|YYm= MmP0OVDDqM7:TR?= MnvBNYg> MYfpcohq[mm2czDISk1qdmS3Y3XkJIFxd3C2b4Ppd:Kh M{Th[|IyQTl6N{Ox
HL60 M37B[GFxd3C2b4Ppd{BCe3OjeR?= M3q5c|Qx|ryP M2THWVQxdWmw M1PwcmROW09? M3nOUoJtd2OtczDCUmREKGOxbYDveY5leyCrbnT1Z4Uh\Xiyb4P1doUhd2ZicHjvd5Bp[XSrZInsd4VzcW6nIHHu[EBFVkFiZoLh[41mdnSjdHnvci=> NV\jO3dqOjF7OEOyPVY>
M-14 MVTBdI9xfG:|aYOgRZN{[Xl? NEXxfVkzPc7:TR?= NEjWT2UxNjWq NIj2XJPDqGmwaHnibZR{KGKxdHigeIhmKGO{dXTlJIV5fHKjY4StJIFv\CClb33wc5Vv\C2rbnT1Z4VlKGGyb4D0c5Nqew>? M2ryRlIyQTV2OUW5
SK-BR-3 NGrSOnNCeG:ydH;zbZMhSXO|YYm= M{DYeFUxyqEQvF2= MkT6Nog> M{HnPIJtd2OtczDhdI9xfG:2aXOgSG5CKG[{YXft[Y51[XSrb36gbY5lfWOnZDDifUBkd22kaX7heIlwdiCxZjDTUU0yPjRiYX7kJJJi\GmjdHnvci=> Mm\ENlE6ODF|OE[=
MDA-MB-468 NUX4VXk4SXCxcITvd4l{KEG|c3H5 MX[1NOKh|ryP M3qyUlJp NF7meGhjdG:la4OgZZBweHSxdHnjJGRPSSCocnHncYVvfGG2aX;uJIlv\HWlZXSgZpkh[2:vYnnuZZRqd25ib3[gV20uOTZ2IHHu[EBz[WSrYYTpc44> NXXqdohOOjF7MEGzPFY>

... Click to View More Cell Line Experimental Data

In vivo In vivo Z-VAD-FMK administration has been shown previously to be nontoxic and to prevent apoptosis in animal models. Intraperitoneal HK-GBS injection leads to preterm delivery, and pretreatment with Z-VAD-FMK delays preterm delivery in mice. In OVA-sensitized mice,treatment of z-VAD-fmk inhibits allergen-induced leukocyte infiltration. Systemic injection of the pan-caspase inhibitor z-VAD-fmk immediately before OVA challenge reduced inflammatory cell accumulation, mucus hypersecretion, and Th2 cytokine release in OVA-sensitized/challenged mice. Treatment with z-VAD-fmk blocked terminal differentiation of lens epithelial cells and keratinocytes, the differentiation of monocytes into macrophages, and the differentiation of erythroid progenitors. z-VAD-fmk attenuated allergen-induced airway inflammation and hyperreactivity. Treatment with z-VAD-fmk in vivo also prevented subsequent T cell activation ex vivo[7].

Protocol

Cell Research:

[6]

+ Expand
  • Cell lines: human granulosa cell lines (GC1a, HGL5, COV434)
  • Concentrations: 50 μM
  • Incubation Time: 48 h
  • Method:

    To validate the efficacy of Z-VAD-FMK, three human granulosa cell lines (GC1a, HGL5, COV434) were treated for 48 h with etoposide (50 μg/ml) and/or Z-VAD-FMK (50 μM) under normoxic conditions. To mimic the ischemic phase that occurs after ovarian fragment transplantation, cells were cultured without serum under hypoxia (1 % O2) and treated with Z-VAD-FMK. The metabolic activity of the cells was evaluated by WST-1 assay. Cell viability was determined by FACS analyses. The expression of apoptosis-related molecules was assessed by RT-qPCR and Western blot analyses.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: CD1 mice
  • Formulation: dissolved in DMSO, diluted in PBS (final concentration of DMSO < 1%)
  • Dosages: 10 mg/kg
  • Administration: i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 93 mg/mL (198.93 mM)
Water Insoluble
Ethanol Insoluble warmed
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+35 %PEG 300+2%Tween 80+ddH2O
For best results, use promptly after mixing.
6mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 467.49
Formula

C22H30FN3O7

CAS No. 187389-52-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Can you suggest an in vivo formulation of S7023 for animal studies?

  • Answer:

    For in vivo study of S7023, The IP formulation is 2% DMSO+35 % PEG 300+2% Tween 80+ddH2O up to 6 mg/ml. The gavage formula is 1%CMC-Na up to 30 mg/ml (suspensions).

  • Question 2:

    What is difference between S7023 & S8102?

  • Answer:

    Unlike S7023, S8102 does not require pretreatment with esterase for in vitro studies. This information was cited from the article: https://www.ncbi.nlm.nih.gov/pubmed/16973565.

Caspase Signaling Pathway Map

Related Caspase Products

Tags: buy Z-VAD-FMK | Z-VAD-FMK supplier | purchase Z-VAD-FMK | Z-VAD-FMK cost | Z-VAD-FMK manufacturer | order Z-VAD-FMK | Z-VAD-FMK distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID